Company Overview and News
VANCOUVER, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Acadian Timber Corp.'s (TSX: ADN) 2018 Third Quarter Conference Call & Webcast on November 1, 2018 at 1:00 p.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives.
VANCOUVER, British Columbia, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Acadian Timber Corp. (“Acadian” or the “Company”) (TSX:ADN) today reported financial and operating results1 for the three months ended June 30, 2018 (the “second quarter”).
VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Acadian Timber Corp.'s 2018 Second Quarter Conference Call & Webcast on August 2, 2018 at 1:00 p.m. (Eastern Time) to discuss results and current business initiatives with members of senior management.
VANCOUVER, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Acadian Timber Corp. (TSX:ADN) (“Acadian Timber” or the “Company”) announced that the nominees listed in the management proxy circular for the 2018 Annual Meeting of Shareholders were elected as directors of the Company. Detailed results of the votes by proxy for the election of directors held at the Annual Meeting of Shareholders today in Toronto are set out below.
Investors, analysts and other interested parties can access Acadian Timber Corp.’s 2018 First Quarter Results via conference call or webcast on Tuesday May 8, 2018 at 9:00AM ET, please dial 1-866-521-4909 toll free in North America (Canada and the USA), or for overseas calls, please dial 1-647-427-2311 at approximately 8:50AM ET. For those unable to participate, a taped rebroadcast will be available until midnight June 8, 2018.
You are invited to participate in Acadian Timber Corp.'s 2018 First Quarter Conference Call & Webcast on May 8th, 2018 at 9:00 a.m. (Eastern Time) to discuss results and current business initiatives with members of senior management.
38 of 77 Basic Materials top yield stocks were tagged "safer" for dividends because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields 3/23/18.
ICL RIO ADN RIO BLT 0336 RTPPF HUABF MERC RTNTF CELTF BHPBF WLK UFS SOUHY AAL ACAZF WLKP VEDL MRI.U BHP RIO AAUKF BBL BHP BHPLF NGLOY VEDL HUIHY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:ADN / Acadian Timber Corp on message board site Silicon Investor.